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DNA methylation in juvenile idiopathic arthritis
reveals potential targets involved in disease
Justine A Ellis1,8*, Jane E Munro2,3, Raul A Chavez1, Lavinia Gordon4, Jihoon E Joo5,6, Jonathan D Akikusa2,3,
Roger C Allen2,3, Anne-Louise Ponsonby7, Jeffrey M Craig5 and Richard Saffery6Abstract
Background: Juvenile Idiopathic Arthritis (JIA) is a complex autoimmune rheumatic disease of largely unknown
cause. Evidence is growing that epigenetic variation, particularly DNA methylation, is associated with autoimmune
disease. However, nothing is currently known about the potential role of aberrant DNA methylation in JIA. As a first
step to addressing this knowledge gap, we have profiled DNA methylation in purified CD4+ T cells from JIA
subjects and controls. Genomic DNA was isolated from peripheral blood CD4+ T cells from 14 oligoarticular and
polyarticular JIA cases with active disease, and healthy age- and sex-matched controls. Genome-scale methylation
analysis was carried out using the Illumina Infinium HumanMethylation27 BeadChip. Methylation data at >25,000
CpGs was compared in a case-control study design.
Results: Methylation levels were significantly different (FDR adjusted p<0.1) at 145 loci. Removal of four samples
exposed to methotrexate had a striking impact on the outcome of the analysis, reducing the number of
differentially methylated loci to 11. The methotrexate-naive analysis identified reduced methylation at the gene
encoding the pro-inflammatory cytokine IL32, which was subsequently replicated using a second analysis platform
and a second set of case-control pairs.
Conclusions: Our data suggests that differential T cell DNA methylation may be a feature of JIA, and that reduced
methylation at IL32 is associated with this disease. Further work in larger prospective and longitudinal sample
collections is required to confirm these findings, assess whether the identified differences are causal or
consequential of disease, and further investigate the epigenetic modifying properties of therapeutic regimens.
Keywords: Epigenetics, Juvenile idiopathic arthritis, DNA methylation, Autoimmunity, Methylome, MethotrexateBackground
Juvenile Idiopathic Arthritis (JIA) is the most common
autoimmune rheumatic disease of childhood. The aetiology
of JIA remains largely unknown, but as for other auto-
immune diseases, including adult rheumatoid arthritis, the
interplay between genes and environment is likely to be
important [1]. A potential conduit for such interactions to
alter disease risk is via epigenetic modification, defined as
“the structural adaptation of chromosomal regions so as to* Correspondence: justine.ellis@mcri.edu.au
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reproduction in any medium, provided the orregister, signal or perpetuate altered activity states” [2]. For
example, methylation of CpG dinucleotides at gene pro-
moters is generally associated with a reduction in gene ex-
pression. Folate, through one-carbon metabolism, is an
important primary methyl donor (reviewed in [3]), and
maternal folate intake has been shown to alter epigenetic
profile and resultant phenotypes of offspring in rodents
[4]. In humans, studies of monozygotic twin pairs have
demonstrated modification of epigenetic profile across the
life course in response to environmental exposure
(reviewed in [5]).
A growing body of evidence suggests that epigenetic
modification plays an important role in specifying risk
associated with autoimmune disease [6]. Unequivocal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sponse. For example the expression of cytokines such as
interleukin 4 (IL4) and interferon gamma (IFNγ) that drive
naive T cells to differentiate into T helper 1 (Th1) or Th2
lineages is epigenetically controlled [6,7]. Immune toler-
ance is also associated with epigenetic changes, for ex-
ample increased DNA methylation of the gene encoding
IL2, an important T cell growth factor, leads to reduced
IL2 expression and decreased T cell proliferation [8]. Epi-
genetic involvement in a number of autoimmune diseases
has been considered; one of the most well studied is sys-
temic lupus erythematosus (SLE), a disease associated with
global T cell and B cell hypomethylation [9] and changesTable 1 Genes associated with probes identified by Infinium
differentially methylated (a) between all cases and controls (
Additional file 1: Table S2), and (b) between MTX-naïve cases
Gene p value Adjusted p value* B Case rel
(a) ALDOB 6.64E-05 0.069 1.727
C8ORFK32 4.09E-05 0.067 2.146
DGKH 6.38E-05 0.069 1.762
FLJ20581 2.65E-05 0.067 2.519
FLJ36004 4.65E-05 0.067 2.036
GCET2 5.88E-06 0.067 3.803
GRM5 3.36E-05 0.067 2.317
GYPE 1.72E-05 0.067 2.893
LILRB4 3.39E-05 0.067 2.309
LOC90826 1.22E-05 0.067 3.185
MEF2C 3.57E-05 0.067 2.263
MRPL28 4.03E-05 0.067 2.159
NR1I2 3.38E-05 0.067 2.311
PRH1 2.84E-05 0.067 2.461
RAD51L3 4.58E-05 0.067 2.049
Rgr 4.12E-06 0.067 4.102
SCOC 4.74E-05 0.067 2.019
SLC13A3 2.35E-05 0.067 2.624
TIMM8B 1.56E-05 0.067 2.972
TRAM1L1 4.51E-05 0.067 2.063
(b) PRKRA 7.51E-07 0.019 4.225
HOXB4 3.46E-06 0.044 3.177
C6orf203 1.02E-05 0.049 2.415
HCRTR1 1.20E-05 0.049 2.300
C9orf43 1.23E-05 0.049 2.281
LIN37 1.31E-05 0.049 2.239
MEP1A 1.63E-05 0.049 2.084
NDUFB10 1.79E-05 0.049 2.018
RCAN2 1.82E-05 0.049 2.003
IL32 1.91E-05 0.049 1.969
SOCS2 2.35E-05 0.054 1.821
* P value following adjustment for false discovery rate (FDR).
B = log-odds that the probe is differentially methylated.to the methylation state of specific gene loci [10]. Aberrant
DNA methylation has also been implicated in rheumatoid
arthritis (RA), with reduced DNA methylation reported in
peripheral blood mononuclear cells (PBMC) [11], T cells
[12] and synovial cells [13], including at a specific CpG site
at the gene encoding the pro-inflammatory cytokine IL6
[14]. Hypermethylation of the promoter region of the gene
encoding death receptor 3 (DR3), a member of the
apoptosis-inducing tumor necrosis factor (TNF) receptor
superfamily, has also been reported in RA synovial cells
[15].
Despite the mounting evidence for epigenetic disrup-
tion in autoimmune rheumatic diseases, no studies toHumanMethylation27K BeadChip array as significantly
20 most significant loci shown – for a full list refer to
and controls
ative to control Median controls Median cases Difference
Higher 0.715 0.791 0.075
Higher 0.754 0.794 0.040
Lower 0.114 0.089 0.025
Higher 0.877 0.924 0.047
Higher 0.738 0.823 0.085
Lower 0.152 0.107 0.044
Higher 0.78 0.846 0.066
Higher 0.688 0.781 0.093
Higher 0.823 0.866 0.043
Lower 0.142 0.091 0.051
Lower 0.075 0.056 0.019
Lower 0.875 0.685 0.190
Higher 0.842 0.89 0.047
Higher 0.813 0.875 0.062
Lower 0.277 0.202 0.075
Higher 0.894 0.931 0.037
Higher 0.765 0.825 0.060
Higher 0.712 0.784 0.073
Lower 0.124 0.079 0.045
Lower 0.224 0.142 0.083
Higher 0.061 0.063 0.002
Lower 0.073 0.064 0.009
Lower 0.095 0.084 0.011
Higher 0.659 0.716 0.057
Higher 0.043 0.046 0.003
Higher 0.031 0.032 0.001
Higher 0.882 0.927 0.045
Higher 0.026 0.027 0.001
Higher 0.879 0.906 0.027
Lower 0.335 0.298 0.037
Lower 0.098 0.076 0.022
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ant not only for understanding aetiology, but also be-
cause the modifiable nature of epigenetic marks makes
them ideal therapeutic targets [16]. As a first attempt to
address this knowledge gap, we have performed a
genome-scale comparison of CD4+ T cell DNA methyla-
tion at over 27,000 CpG sites associated with over
14,000 genes in 14 children with active JIA (10 oligoarti-
cular and 4 polyarticular) and 14 age- and sex-matched
healthy control children.Figure 1 Heatmap of significantly differentially methylated loci betwee
methylation.Results
Differential methylation between cases and controls
Greater than 97% of HM27 probes passed QC measures
with technical replicates demonstrating a high degree of
reproducibility (Additional file 1: Figure S1). Following ad-
justment of p values for false discovery rate (FDR), probes
associated with 145 genes were significantly different
(adjusted p value < 0.1) between cases and controls
(Table 1 a, Additional file 1: Table S1). A total of 91 genes
were more highly methylated in cases, whilst 54 weren JIA cases and controls. Black = case, Grey = control. ‘Value’ = percent
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ing demonstrated that cases and controls did not cluster
by phenotype (Figure 1), which might be expected for a
complex disease such as JIA [1].Gene ontology and pathway analyses
Gene ontology analyses of gene-associated differentially
methylated probes in cases versus controls identified dicar-
boxylic acid transport as a significantly perturbed biological
process (p = 0.0004), the mitochondria as a significant cel-
lular component (p = 0.0006), and the L-aspartate trans-
membrane transporter activity as a significantly perturbed
molecular function (p = 0.0006).
IPA software was used to identify networks amongst
the differentially methylated loci. Twenty one genes fell
into a network for which the top function was ‘immuno-
logical disease’, 16 genes fell into a network for which
the top function was identified as ‘cellular growth and
proliferation’, and 15 genes fell into a network in which
the top functions included ‘antigen presentation’ and
‘cell-to-cell signalling and interaction’. Genes falling into
these classifications are shown in Table 2.Consideration of JIA subtypes
In recognition of the potential genetic heterogeneity be-
tween the oligoarticular and polyarticular JIA subtypes
[17], differential methylation between cases and controls
was considered within the subtype groups. Only one
locus, SPATA16 (spermatogenesis associated 16),
remained significant (Padj = 0.056) when the 10 oligoarti-
cular JIA cases (mean β = 0.84) were compared to their
matched controls (mean β = 0.87). SPATA16 has been
associated with male infertility [18], but has no known
relationship to arthritis or autoimmune disease.
Not surprisingly, given the limited sample size, no loci
were significantly differentially methylated when the four
polyarticular cases were compared to matched controls.Table 2 Differentially methylated (DM) genes identified as fal
(a) between all cases and controls, and (b) between MTX-naïv
Top network functions
(a) Immunological disease, cardiac hypertrophy,
cardiovascular disease
Cellular Growth and Proliferation, Gene Expression,
Cellular Movement
Antigen Presentation, Cell-To-Cell Signaling and Interaction,
Hematological System Development and Function
(b) Cellular growth and proliferation, Haematological system
development and function, HematopoiesisAn effect of methotrexate on DNA methylation profile in
JIA?
In recognition of the potential impact of the disease
modifying anti-rheumatic drug (DMARD) methotrexate
(MTX, a folate metabolism inhibitor [19]), on DNA
methylation, we subsequently removed four cases from
the array data that had been exposed to MTX prior to
the collection of T cells. Case-control comparisons were
run again, resulting in a total of 11 significantly (P<0.1)
differentially methylated probes following FDR adjust-
ment, associated with 11 different genes (Table 1 b).
These genes did not overlap with those identified by the
original analysis. Hierarchical clustering based on these
11 loci did not clearly delineate cases from controls
(Additional file 1: Figure S2).
The number of identified genes was insufficient for a
meaningful GO analysis. IPA analysis of genes within
this list identified ‘cellular growth and proliferation,
haematological system development and function,
hematopoiesis’ as the top network, involving 9 of the 10
characterised differentially methylated genes (Table 2,
Figure 2). The top three biological functions were ‘con-
nective tissue development and function’, ‘skeletal and
muscular system development and function’, and ‘tissue
development’. The top two identified canonical pathways
were ‘IL9 signalling’, and ‘role of JAK2 in hormone-like
cytokine signalling’.Validation of HM27 methylation differences and
replication in an additional JIA sample
In order to confirm validity of the HM27 data, we mea-
sured gene-specific methylation of two differentially
methylated genes, MRPL28 and IL32, by Sequenom
MassARRAY Epityper analysis. For validation, methyla-
tion was measured in the ‘discovery’ (array) case-control
pair set (where sufficient DNA was available). Addition-
ally, we attempted to replicate the observed differentialling within the top networks using IPA pathway analysis
e cases and controls
# DM genes Genes
21 APOE, ATP2B4, CARD8, CASP8, CAV3,
COL17A1, DOK2, ESR2, HRSP12, IL1RL1,
ITGA6, MEF2C, NR1D1, NR1I2, PLUNC,
PSMC5, RETN, SELL, SPA17, SPOP, TLR6
16 ANGEL2, ARMC1, C11orf49, CBARA1,
FXC1, KIAA0196, KRT10, LCN12, MRPL28,
MTRF1, NR1D1, PSMB5, PSMC5, RBM18,
RSL24D1, TFB1M
15 AKAP6, ARFGEF1, BCKDHB, CDS2,
CEACAM3, CPT2,CRB1, GCET2,
GPD2, LY9, RAB32,RBP3, SLC1A6,
TIMM8B, ZKSCAN3
9 HCRTR1, HOXB4, IL32, LIN37, MEP1A,
NDUFB10, PRKRA, RCAN2, SOCS2
Figure 2 Ingenuity pathway analysis (IPA) top network that incorporates 9 genes identified as differentially methylated between
methotrexate-naïve cases and controls by HM27 analysis.
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‘replication’ pair set (Additional file 1: Table S2).
MRPL28 was chosen for validation because of the large
HM27 case-control β value differences observed (Figure 3A,
Additional file 1: Table S3). We quantitatively measured
methylation at 11 CpG dinucleotides within 8 assay units at
MRPL28 (Additional file 1: Figure S3), including the HM27
differentially-methylated probe (DMP) site (assay unit
CpG_14.15). Across the entire dataset, β values for the
HM27 DMP and assay unit CpG_14.15 were significantlycorrelated (r = 0.92, p <0.0001). Large case-control Δβ
values were observed for several Sequenom CpG assay
units, especially those lying in close proximity to the HM27
probe (Additional file 1: Table S3). Figure 3A presents box-
plots of methylation values obtained from the array probe
in the discovery case-control samples, and from Sequenom
assay unit CpG_14.15 in the discovery and replication case-
control samples. Conditional logistic regression demon-
strated significant (p < 0.05) association of JIA with lower
methylation levels at three of the measured CpG units,
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Figure 3 Boxplots of validation and replication JIA case-control data for differentially methylated genes MRPL28 and IL32. (A) HM27
MRPL28 array data (probe cg12437481) for the discovery case-control pairs, and MRPL28 sequenom data (assay unit CpG_14.15 – see Additional
file 1: Figure S3) for the discovery and replication case-control pairs. (B) HM27 IL32 array data (probe cg18350391) for the discovery case-control
pairs, and IL32 sequenom data (assay unit CpG_10 – see Additional File 1: Figure S4) for the discovery and replication case-control pairs.
Comparing array and sequenom data for the discovery samples demonstrates validation of array data, and comparing sequenom data between
the discovery and replication samples demonstrates replication of the direction of effect and magnitude of difference between the cases and
controls at these loci.
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tion equates to a 10% decrease in risk of being a JIA case
(Odds Ratio (OR) = 0.90, 95% CI 0.81, 0.99; p = 0.026). For
all Sequenom assay units, mean β values were lower in cases
than controls, consistent with the direction of difference
observed by HM27. Finally, this direction of difference was
consistently observed when both the discovery and replica-
tion case-control pair groups were considered separately for
all but one CpG unit measured (Additional file 1: Table S3),
suggesting that such differences are genuinely associated
with the JIA phenotype.
We also quantitatively measured methylation at 10 CpG
sites within 9 assay units at the pro-inflammatory cytokine
gene IL32. IL32 was identified as differentially methylated
between cases and controls following removal of MTX-
exposed cases from analysis, and as a pro-inflammatory
cytokine, was considered a physiologically plausible candi-
date gene. The HM27 DMP was directly captured by the
Sequenom assay (CpG_10, see Additional file 1: Figure
S4). Methylation was measured in both the discovery and
replication pair sets following removal of MTX-exposed
pairs 1, 4, 10, 13, and 19 (Additional file 1: Table S2).
Across the entire dataset, β values for the HM27 differen-
tially methylated probe and assay unit CpG_10 were sig-
nificantly correlated (r = 0.70, p = 0.0008). Case-control
Δβ values were largest for CpG_10 and neighbouring
CpG_9; this was most striking in the discovery pair set,
but of consistent direction in the replication pair set
(Additional file 1: Table S4). Figure 3B presents boxplots
of methylation values obtained from the array probe in the
discovery case-control samples, and from Sequenom assay
unit CpG_9 in the discovery and replication case-control
samples. Conditional logistic regression of the combined
dataset demonstrated nominally significant association of
JIA with lower methylation at CpG_9, such that a 1% in-
crease in methylation equates to a 6% decrease in risk of
being a JIA case (OR = 0.94, 95% CI: 0.87, 1.00; p = 0.064).
Significant associations were not detected when the dis-
covery or replication datasets were considered separately,
although the direction of effect was the same (discovery
sample OR = 0.92, 95% CI: 0.83, 1.03, p = 0.13; replication
sample OR = 0.95, 95% CI: 0.87, 1.04, p = 0.26), suggestive
of replication and genuine association.
Discussion
We present the first report of genome-scale analysis of DNA
methylation profile in JIA. We have identified 145 differen-
tially methylated loci of which 91 are more highly methylated
in cases. Significant case-control differences are generally
modest (difference in median β ranging from 0.006 – 0.19),
however, this is consistent with a growing number of other
equivalent studies in complex disease (reviewed in [20]).
Pathway analyses of genes subject to altered DNA methyla-
tion identified autoimmune disease-relevant networks ofgenes including ‘immunological disease’, ‘cellular growth and
proliferation’, and ‘antigen presentation’.
Four case samples used in the HM27 analysis had
prior exposure to the commonly used DMARD, MTX.
The anti-inflammatory properties of MTX are yet to be
fully understood, but may include inhibition of T cell
activation, induction of T cell apoptosis, and/or alter-
ation of expression of cytokines [21]. Importantly for
DNA methylation, MTX is an anti-folate agent. Folates
are micronutrients essential for one-carbon metabolism,
a process of methyl group transfer essential for the spe-
cific methylation of cytosine nucleotides within CpG
sites [3]. Thus, it is reasonable to hypothesise that MTX
may impact the T cell methylome in exposed cases.
Whilst we cannot, from our data, provide conclusive evi-
dence in support of this hypothesis, removal of MTX-
exposed cases from the array analysis did have a striking
impact on the outcome: the number of differentially
methylated genes was reduced from 145 to 11; and none
of the genes from the first- and second-tier analyses
overlapped. While it remains possible that the contrast-
ing outcomes were due to other factors, for example, the
MTX-exposed cases may have been in other ways clinic-
ally distinct from the MTX-naive cases, our data does
suggest a potential impact of MTX on DNA methyla-
tion. However, we found no evidence to suggest that this
impact is genome-wide since mean β values across the
>25,000 HM27 probes analysed was not different be-
tween exposed and unexposed cases (t-test p = 0.85).
Unfortunately our sample size was insufficient for a
meaningful locus-by-locus comparison of MTX-exposed
and -naive case samples within this study, but overall
our work suggests that data derived from MTX-exposed
samples should be treated with caution in epigenome-
wide association studies. Further investigation of this
issue using a larger sample of MTX naive and exposed
individuals is warranted, especially in light of recently
published rheumatoid arthritis methylome data derived
from case samples of mixed MTX exposure status [22].
Pathway analysis based on the 11 MTX-naive differen-
tially methylated genes defined a network related to ‘cellu-
lar growth and proliferation, haematological system
development and function, hematopoiesis’ within which
nine of the 10 characterised genes were placed. Central to
this network is the pro-inflammatory cytokine TNF. TNF
initiates a pro-inflammatory programme of events asso-
ciated with autoimmune and inflammatory diseases [23],
including JIA [24]. TNF blockers have been used for some
time as a treatment for JIA [25]. Therefore, aberrant
methylation of a network of differentially methylated
genes in T cells of children with JIA may result in the pro-
motion of a disease-relevant inflammatory cascade.
Of the MTX-naive differentially methylated loci, IL32
stands out as an interesting finding. IL32 is a pro-
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TNF. TNF also induces IL32 expression and the two
molecules form an important autoinflammatory loop, as
demonstrated in RA synovial cells [26]. Mice overex-
pressing IL32 show higher serum concentrations of
TNF, and exacerbation of collagen-induced arthritis [27].
In our study, specific IL32 CpGs measured by both
genome-scale and locus specific analyses were seen to be
less methylated in cases than in controls across two dis-
tinct sample sets, suggesting higher levels of expression.
A limitation of our study is that we did not collect CD4
+ T cell RNA to measure gene expression, although evi-
dence does exist to suggest IL32 expression is dependent
on methylation [28]. Thus, further work will be required
to assess the relationship between IL32 DNA methyla-
tion and IL32 gene expression in JIA.
The locus-specific replication data for MRPL28 is also
interesting. Although MRPL28 was not seen to be sig-
nificantly differentially methylated in the MTX-naive
array analysis (FDR p = 0.47), significantly reduced
methylation in cases relative to matched controls, (Δβ
values in excess of 0.2), was found for pairs containing
both MTX-exposed and -naive cases across discovery
and replication samples. MRPL28 encodes mitochondrial
ribosomal protein L28, the function of which is poorly
described. It is therefore difficult to speculate as to how
reduced MRPL28 methylation might increase JIA risk,
although mitochondrial dysfunction has been associated
with autoimmune disease [29]. Again, further work will
be required to more fully interpret these findings.
An important issue that needs to be addressed in epi-
genetic research such as that presented here, is whether
or not any identified disease-associated changes to the
epigenome precede disease onset, or result from the dis-
ease process. Identification of aberrant DNA methylation
that precedes disease suggests that such changes may
contribute to risk of developing disease, and could there-
fore act as biomarkers to identify at-risk individuals and
contribute to our understanding of the genomic under-
pinnings of causality. However, for relatively rare com-
plex diseases like JIA, it is very difficult to prospectively
collect cases, since the size of the prospective cohort ne-
cessary to identify sufficient cases would be very large.
One approach to the problem is to retrospectively obtain
diagnostic biospecimens collected routinely at birth,
such as neonatal dried blood spots. Methods have now
been developed to measure locus-specific DNA methyla-
tion in dried blood spots [30], and in the future this may
well extend to the use of these specimens on a genome-
scale. The CLARITY Biobank now encompasses neo-
natal dried blood spots from recruited cases and con-
trols, and is shortly commencing longitudinal
biospecimen collection for cases across the disease
course. Thus, a future important research direction willbe to examine changing methylation levels periodically
from birth through to disease resolution.
Conclusions
We have demonstrated genome-scale differences in T
cell DNA methylation profiles in children with JIA com-
pared to age- and sex-matched healthy controls. Our
data suggests a potential impact of MTX treatment on
the methylome, therefore selecting DMARD-naive bios-
pecimens for future epigenetic research of this kind may
be important. Finally, in two groups of case-control pairs
across two different analysis platforms, methylation at
MRPL28 and IL32 appears reduced in the T cells of chil-
dren with JIA, and these findings were robust to MTX
exposure. Other genes highlighted by the genome-scale
analyses require further exploration. However, our data
provides strong impetus to further consider the role of
DNA methylation in JIA risk and in disease course, at
higher genome-scale resolution and at specific loci, in
larger sample sizes.
Methods
Participant recruitment and selection
Cases and controls were recruited as part of CLARITY
(ChiLdhood Arthritis Risk factor Identification sTudY),
an ongoing study of the genetic and environmental risk
factors of JIA. Recruitment is ongoing, and commenced in
2008 at the Royal Children’s Hospital (RCH), Melbourne,
Victoria Australia. Cases were defined as children meeting
the International League of Associations for Rheumatology
(ILAR) criteria [31] for the diagnosis of JIA. Cases were
considered incident if they were recruited to the study
within six months of initial diagnosis to allow for definition
of ILAR subtype. Controls were otherwise well children
≤16 years admitted for minor surgical procedures. All
protocols were approved by the RCH Human Research
Ethics Committee.
For the genome-scale methylation array analysis, 14
cases (mean age 9.1 yrs, SD 4.2 yrs; 71.4% female; 10 oli-
goarticular, 4 polyarticular), were selected. The high per-
centage of female case samples reflects the predominance
of females amongst those with oligoarticular and polyarti-
cular JIA in the population. Cases were then matched to a
control by age and sex. The basic characteristics of each
‘discovery’ case-control pair is shown in Additional file 1:
Table S2 (pair numbers 1-14). All cases had active disease,
and all were incident with the exception of cases in pairs 4
and 10.
An additional set of 12 incident cases (mean age 7.2
yrs, SD 4.2 yrs; 75.0% female; 9 oligoarticular, 3 polyarti-
cular) and matched controls were selected in a similar
fashion for replication of array-detected differentially
methylated loci using the Sequenom MassARRAY plat-
form. The basic characteristics of each ‘replication’ case-
Ellis et al. Clinical Epigenetics 2012, 4:20 Page 9 of 11
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numbers 15-26).
T cell DNA isolation and genome-scale methylation
analysis
Each participant provided a 9ml peripheral blood sample.
Plasma was removed within two hours of collection and
stored. PBMCs were isolated using standard Ficoll gradi-
ent procedures within 24 hours of collection, and stored
in liquid nitrogen. Total CD3+ CD4+ T cells were posi-
tively selected from the PBMC population using flow cyto-
metry (Becton Dickinson (San Jose, CA, USA) antibodies,
cat# 340440, 347327). T cell purity was very high (typically
~99%) following cell sorting. DNA was extracted using the
Flexigene DNA extraction kit (Qiagen) and bisulphite con-
verted using the MethylEasy Xceed (Human Genetic Sig-
natures, Randwick, NSW, Australia) kit according to
manufacturer’s instructions. Converted DNA was then ap-
plied to the Illumina Infinium HumanMethylation27
BeadChip arrays (HM27) (ServiceXS, The Netherlands).
These arrays measure methylation at an average of 2 CpG
sites in the promoter regions of 14,475 genes and 110
miRNA promoters (27,578 sites tested in all). DNA from
each case and its matched control was hybridised to the
same array chip to avoid confounding of results by chip
variability. DNA samples from one case-control pair (pair
number 13) were applied twice to the same chip as tech-
nical replicates.
Genome-scale methylation data analysis
All analyses were carried out using the statistical program-
ming language R (www.r-project.org) (version 2.12.0)
using packages from the Bioconductor project [32]. Data
quality was confirmed using arrayQualityMetrics [33],
which produces a number of diagnostic plots to assess re-
producibility, identifies apparent outlier arrays and com-
putes measures of the signal-to-noise ratio.
Probes considered to overlap SNPs [34] were removed,
along with those on the X and Y chromosomes, reducing
the number of probes from 27,578 to 26,422. The lumi
package [35,36] was used to calculate the log2 ratios for
methylated probe intensity to unmethylated probe inten-
sity (M-values). These values underwent colour-adjust-
ment, background correction and ssn normalization. All
probes failing a detection p-value cut-off of < 0.01 were
removed. This reduced the number of probes available
to 25,303 probes (13,462 unique genes). These probes
were subsequently passed to limma [37] for differential
methylation analysis. Array weights were calculated,
thereby estimating relative quality weights for each array
[38]. A linear model was fitted testing for the difference
between cases and controls. P-values were adjusted for
multiple testing using the Benjamini and Hochberg
method [39]. M-values were converted to β-values(equivalent to percent of alleles methylated at each site)
and subsequently used to calculate the correlation be-
tween the technical replicates.Gene Ontology and Pathway Analyses
Testing was carried out for the association of Gene
Ontology (GO) terms in the list of significantly differen-
tially methylated genes using the Bioconductor package
GOstat [40]. Specifically an analysis was carried out to
look for overrepresentation of GO terms using a hyper-
geometric test. Ingenuity Pathway Analysis (IPA) soft-
ware (Ingenuity Systems, Redwood City, CA, USA) was
used to investigate pathways and relationships between
differentially methylated genes. The full list of gene loci
measured by the HM27 was used as the reference set in
these analyses.Validation of case-control methylation differences using
the Sequenom MassARRAY Epityper platform
Validation of array-detected methylation differences be-
tween cases and controls at chosen loci was performed
using the Sequenom (San Diego, CA, USA) MassARRAY
platform as previously described [41]. Assays were
designed using the Epidesigner software (http://www.epi-
designer.com) to capture methylation at CpG sites sur-
rounding the HM27 array probe, with the exact HM27
CpG site measured where possible (Additional file 1:
Figures S3 and S4). Data points were removed where dif-
ferences in duplicate beta values exceeded 0.2, otherwise
the average was taken. Stata v11 (StataCorp, College Station,
TEX, USA) was used to perform HM27-Sequenom data cor-
relation analyses and conditional logistic regression analyses
(taking into account the matched-pair design) to examine
the differences in methylation β values (converted to %
methylation by multiplying β values by 100) between cases
and controls.Additional file
Additional file 1: Figure S1. Correlation in betas between technical
replicates. Table S1. Alphabetical list of genes associated with probes
identified as significantly differentially methylated between cases and
controls. Figure S2. Heatmap of significantly differentially methylated loci
between MTX-naïve JIA cases and controls. Figure S3. Location of
MRPL28 CpG dinucleotides measured by the Sequenom Epityper assay.
Figure S4. Location of IL32 CpG dinucleotides measured by the
Sequenom Epityper assay. Table S2. Basic characteristics of the age- and
sex-matched case-control pairs. Table S3. Beta values for MRPL28
Sequenom EpiTYPER assay units, in comparison to beta values from the
significantly differentially methylated MRPL28 HM27 array probe. Table
S4. Beta values for IL32 Sequenom EpiTYPER assay units, in comparison
to beta values from the significantly differentially methylated IL32 HM27
array probe.
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